FLUBLOK QUADRIVALENT Rx
Generic Name and Formulations:
Quadrivalent, recombinant hemagglutinin (virus types A and B); contains a total of 180mcg recombinant hemagglutinin per 0.5mL dose; formulation changes annually; soln for IM inj; egg-, antibiotic-, preservative-free.
Sanofi Pasteur, Inc.
Indications for FLUBLOK QUADRIVALENT:
≥18yrs: 0.5mL by IM inj once in the deltoid.
3–<18yrs: not established.
Guillain-Barre syndrome within 6 weeks of previous flu vaccine. Immunosuppressed. Have appropriate treatment available to manage anaphylaxis. Pregnancy. Nursing mothers.
Concomitant vaccines: insufficient data (see full labeling). Immunosuppressants: may get suboptimal response.
Inj site tenderness and pain, headache, fatigue, myalgia, arthralgia.
Single-dose prefilled syringes (0.5mL)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib